1. Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery: A systematic top-down approach from synthesis to preclinical testing.
- Author
-
Hönzke S, Gerecke C, Elpelt A, Zhang N, Unbehauen M, Kral V, Fleige E, Paulus F, Haag R, Schäfer-Korting M, Kleuser B, and Hedtrich S
- Subjects
- Administration, Cutaneous, Animals, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents pharmacokinetics, Anti-Inflammatory Agents toxicity, Dexamethasone pharmacokinetics, Dexamethasone toxicity, Disease Models, Animal, Drug Carriers chemistry, Female, Glycerol chemistry, Humans, Inflammation drug therapy, Inflammation pathology, Male, Particle Size, Polyethylene Glycols chemistry, Polymers chemistry, Rats, Rats, Sprague-Dawley, Skin metabolism, Skin Absorption, Skin Diseases drug therapy, Skin Diseases pathology, Dendrimers chemistry, Dexamethasone administration & dosage, Drug Delivery Systems, Nanoparticles
- Abstract
Drug loaded dendritic core-multishell (CMS) nanocarriers are of especial interest for the treatment of skin diseases, owing to their striking dermal delivery efficiencies following topical applications. CMS nanocarriers are composed of a polyglycerol core, connected by amide-bonds to an inner alkyl shell and an outer methoxy poly(ethylene glycol) shell. Since topically applied nanocarriers are subjected to biodegradation, the application of conventional amide-based CMS nanocarriers (10-A-18-350) has been limited by the potential production of toxic polyglycerol amines. To circumvent this issue, three tailored ester-based CMS nanocarriers (10-E-12-350, 10-E-15-350, 10-E-18-350) of varying inner alkyl chain length were synthesized and comprehensively characterized in terms of particle size, drug loading, biodegradation and dermal drug delivery efficiency. Dexamethasone (DXM), a potent drug widely used for the treatment of inflammatory skin diseases, was chosen as a therapeutically relevant test compound for the present study. Ester- and amide-based CMS nanocarriers delivered DXM more efficiently into human skin than a commercially available DXM cream. Subsequent in vitro and in vivo toxicity studies identified CMS (10-E-15-350) as the most biocompatible carrier system. The anti-inflammatory potency of DXM-loaded CMS (10-E-15-350) nanocarriers was assessed in TNFα supplemented skin models, where a significant reduction of the pro-inflammatory cytokine IL-8 was seen, with markedly greater efficacy than commercial DXM cream. In summary, we report the rational design and characterization of tailored, biodegradable, ester-based CMS nanocarriers, and their subsequent stepwise screening for biocompatibility, dermal delivery efficiency and therapeutic efficacy in a top-down approach yielding the best carrier system for topical applications., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF